

ASX ANNOUNCEMENT

14 April 2021

CLEANSING NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT

This cleansing notice (**Cleansing Notice**) is given by Anteris Technologies Ltd (ASX: AVR; **Anteris** or the **Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).¹

The Company advises that it has issued 55,838 ordinary fully paid shares (**Shares**) to Mercer Street Global Opportunity Fund, LLC under a placement.

Details of the securities issued

Class of securities:	Fully paid ordinary shares
ASX code:	AVR
Date of the issue:	12 April 2021
Total number of securities issued:	55,838

Anteris gives notice under section 708A(5)(e) of the Corporations Act 2001 that:

- (a) the Shares have been issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) as at the date of this Cleansing Notice, the Company has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) section 674 of the Corporations Act; and
- (c) as at the date of this Cleansing Notice, there is no 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by Anteris under section 708A(6)(e) of the Corporations Act.

ENDS

¹ As modified by ASIC Instrument 21-0248 dated 7 April 2021 which extends the period of 5 days referred to in sections 708A(5)(b), 708A(12C)(c) and 708AA(2)(c) of the Corporations Act to 6 days in respect of shares and convertible notes issued by Anteris.

Anteris Technologies Ltd

Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service:

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with the unique 3D single-piece aortic valve design of DurAVR™, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Authorisation and Additional information

This announcement was authorised for release by the Board of Directors of Anteris Technologies Ltd.

For more information:

Ms Kyahn Williamson

WE Communications

E: WE-AUAnterisTech@we-worldwide.com

P: +61 401 018 828

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech